Rapport Therapeutics, Inc. (RAPP) stock

RAPPNasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30

$26.15+0.30 (+1.16%)

Close on Nov 13, 2026Market cap $1.25BP/E –Yield –

Rapport Therapeutics EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Rapport Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

See a number that looks wrong?